LB-100
- Generic Name
- LB-100
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C13H20N2O4
- CAS Number
- 1632032-53-1
- Unique Ingredient Identifier
- 0C1JUU9S0L
- Background
LB-100 is under investigation in clinical trial NCT03886662 (A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)).
- Associated Conditions
- -
- Associated Therapies
- -
Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
Phase 2
Completed
- Conditions
- OligodendrogliomasAstrocytoma, Grades II, III and IVGlioblastoma MultiformeGiant Cell GlioblastomaGlioma
- Interventions
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 7
- Registration Number
- NCT03027388
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath